SFRP1 and prostate carcinoma: As SFRP1 downregulation has been linked to epigenetic inactivation in prostate cancer [176,177], further studies to investigate the therapeutic benefit of using DNA methylation drugs for the treatment of advanced prostate cancer is needed.